Aldeyra Therapeutics Completes Enrollment for Phase 2 trial of ADX-2191 for Treatment of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. has announced the completion of the enrollment process for the Phase 2 Clinical Trial of ADX-2191 (methotrexate injection, USP), a potential treatment for retinitis pigmento ...